Cargando…

Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration

BACKGROUND: Newer antiretroviral (ARV) agents have improved pharmacokinetics, potency, and tolerability and have enabled the design of regimens with improved virologic outcomes. Successful antiretroviral therapy is dependent on patient adherence. In previous research, we validated a subset of items...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathews, William C, Barker, Eva, Winter, Erica, Ballard, Craig, Colwell, Bradford, May, Susanne
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2543036/
https://www.ncbi.nlm.nih.gov/pubmed/18759989
http://dx.doi.org/10.1186/1742-6405-5-20
_version_ 1782159172127686656
author Mathews, William C
Barker, Eva
Winter, Erica
Ballard, Craig
Colwell, Bradford
May, Susanne
author_facet Mathews, William C
Barker, Eva
Winter, Erica
Ballard, Craig
Colwell, Bradford
May, Susanne
author_sort Mathews, William C
collection PubMed
description BACKGROUND: Newer antiretroviral (ARV) agents have improved pharmacokinetics, potency, and tolerability and have enabled the design of regimens with improved virologic outcomes. Successful antiretroviral therapy is dependent on patient adherence. In previous research, we validated a subset of items from the ACTG adherence battery as prognostic of virologic suppression at 6 months and correlated with adherence estimates from the Medication Event Monitoring System (MEMS). The objective of the current study was to validate the longitudinal use of the Owen Clinic adherence index in analyses of time to initial virologic suppression and maintenance of suppression. RESULTS: 278 patients (naïve n = 168, experienced n = 110) met inclusion criteria. Median [range] time on the first regimen during the study period was 286 (30 – 1221) days. 217 patients (78%) achieved an undetectable plasma viral load (pVL) at median 63 days. 8.3% (18/217) of patients experienced viral rebound (pVL > 400) after initial suppression. Adherence scores varied from 0 – 25 (mean 1.06, median 0). The lowest detectable adherence score cut point using this instrument was ≥ 5 for both initial suppression and maintenance of suppression. In the final Cox model of time to first undetectable pVL, controlling for prior treatment experience and baseline viral load, the adjusted hazard ratio for time updated adherence score was 0.36(score ≥ 5 )(95% CI: 0.19–0.69) [reference: <5]. In the final generalized estimating equations (GEE) logistic regression model the adjusted odds ratio for time-updated adherence score was 0.17(score ≥ 5 )(0.05–0.66) [reference: <5]. CONCLUSION: A brief, longitudinally administered self report adherence instrument predicted both initial virologic suppression and maintenance of suppression in patients using contemporary ARV regimens. The survey can be used for identification of sub-optimal adherence with subsequent appropriate intervention.
format Text
id pubmed-2543036
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25430362008-09-19 Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration Mathews, William C Barker, Eva Winter, Erica Ballard, Craig Colwell, Bradford May, Susanne AIDS Res Ther Research BACKGROUND: Newer antiretroviral (ARV) agents have improved pharmacokinetics, potency, and tolerability and have enabled the design of regimens with improved virologic outcomes. Successful antiretroviral therapy is dependent on patient adherence. In previous research, we validated a subset of items from the ACTG adherence battery as prognostic of virologic suppression at 6 months and correlated with adherence estimates from the Medication Event Monitoring System (MEMS). The objective of the current study was to validate the longitudinal use of the Owen Clinic adherence index in analyses of time to initial virologic suppression and maintenance of suppression. RESULTS: 278 patients (naïve n = 168, experienced n = 110) met inclusion criteria. Median [range] time on the first regimen during the study period was 286 (30 – 1221) days. 217 patients (78%) achieved an undetectable plasma viral load (pVL) at median 63 days. 8.3% (18/217) of patients experienced viral rebound (pVL > 400) after initial suppression. Adherence scores varied from 0 – 25 (mean 1.06, median 0). The lowest detectable adherence score cut point using this instrument was ≥ 5 for both initial suppression and maintenance of suppression. In the final Cox model of time to first undetectable pVL, controlling for prior treatment experience and baseline viral load, the adjusted hazard ratio for time updated adherence score was 0.36(score ≥ 5 )(95% CI: 0.19–0.69) [reference: <5]. In the final generalized estimating equations (GEE) logistic regression model the adjusted odds ratio for time-updated adherence score was 0.17(score ≥ 5 )(0.05–0.66) [reference: <5]. CONCLUSION: A brief, longitudinally administered self report adherence instrument predicted both initial virologic suppression and maintenance of suppression in patients using contemporary ARV regimens. The survey can be used for identification of sub-optimal adherence with subsequent appropriate intervention. BioMed Central 2008-08-29 /pmc/articles/PMC2543036/ /pubmed/18759989 http://dx.doi.org/10.1186/1742-6405-5-20 Text en Copyright © 2008 Mathews et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mathews, William C
Barker, Eva
Winter, Erica
Ballard, Craig
Colwell, Bradford
May, Susanne
Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration
title Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration
title_full Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration
title_fullStr Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration
title_full_unstemmed Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration
title_short Predictive validity of a brief antiretroviral adherence index: Retrospective cohort analysis under conditions of repetitive administration
title_sort predictive validity of a brief antiretroviral adherence index: retrospective cohort analysis under conditions of repetitive administration
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2543036/
https://www.ncbi.nlm.nih.gov/pubmed/18759989
http://dx.doi.org/10.1186/1742-6405-5-20
work_keys_str_mv AT mathewswilliamc predictivevalidityofabriefantiretroviraladherenceindexretrospectivecohortanalysisunderconditionsofrepetitiveadministration
AT barkereva predictivevalidityofabriefantiretroviraladherenceindexretrospectivecohortanalysisunderconditionsofrepetitiveadministration
AT wintererica predictivevalidityofabriefantiretroviraladherenceindexretrospectivecohortanalysisunderconditionsofrepetitiveadministration
AT ballardcraig predictivevalidityofabriefantiretroviraladherenceindexretrospectivecohortanalysisunderconditionsofrepetitiveadministration
AT colwellbradford predictivevalidityofabriefantiretroviraladherenceindexretrospectivecohortanalysisunderconditionsofrepetitiveadministration
AT maysusanne predictivevalidityofabriefantiretroviraladherenceindexretrospectivecohortanalysisunderconditionsofrepetitiveadministration